menu
    • menu

    Find Atezolizumab manufacturers, exporters & distributors on PharmaCompass

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    4

    API Suppliers

    API Suppliers

    1

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    0

    NDC API

    NDC API

    0

    VMF

    NDC API

    3

    Listed Suppliers

    Other Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    62

    FDF Dossiers

    FDF Dossiers

    3

    FDA Orange Book

    FDA (Orange Book)

    6

    Europe

    Europe

    3

    Canada

    Canada

    48

    Australia

    Australia

    2

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    250DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 0

    GLOBAL SALES INFORMATION

    US Medicaid

    28,732,491

    Annual Reports

    22,288

    Regulatory FDF Prices

    Listed Dossiers
    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    2

    API

    1

    FDF

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    331

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set

    API SUPPLIERS

    read-more
    read-more

    01

    LGM Pharma

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    ChemOutsourcing
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Shanghai Minbiotech

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    IFT FIRST
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Shanghai Minbiotech CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Beijing Mesochem Technology

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI WW Frankfurt
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMesochem is focused on incessant innovation along with the R&D of new APIs.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Mesochem Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Seagen

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    IFT FIRST
    Not Confirmed
    arrow

    Seagen

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    IFT FIRST
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 34785

    Submission : 2020-04-13

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Suppliers

    read-more
    read-more

    01

    LGM Pharma

    U.S.A
    arrow
    ChemOutsourcing
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Atezolizumab

    About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...

    LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, analytical method development and testing, and commercial manufacturing. LGM Pharma offers custom API synthesis, analytical development, and regulatory services. With a network of over 300 accredited CGMP manufacturing partners, LGM provides unparalleled supply chain security. And, with over 100,000 square feet of FDA-inspected cGMP manufacturing and warehouse capacity, LGM Pharma provides a one-stop solution for solid dose, powder, semi-solid and liquid drugs.
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Shanghai Minbiotech

    China
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Atezolizumab

    About the Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...

    ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry.
    Shanghai Minbiotech CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Beijing Mesochem Technology

    China
    arrow
    CPhI WW Frankfurt
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMesochem is focused on incessant innovation along with the R&D of new APIs.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Atezolizumab

    About the Company : Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine c...

    Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine chemicals and fundamental chemical materials. It has an efficient research and development team. Beijing Mesochem provides its customers customized development, craft optimization, contract customization and outsourcing services. The company has a well-established industrial base in Weinan, Shanxi Province. The production base features a 20,000 ㎡ plant with a production capacity of over 8,000 MT per year.
    Mesochem Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

    Details:

    The net proceeds from the offering will be used to advance the clinical development of XTX10 (vilastobart), which is being evaluated for the treatment of mss colorectal cancer.


    Lead Product(s): Vilastobart,Atezolizumab

    Therapeutic Area: Oncology Brand Name: XTX101

    Study Phase: Phase I/ Phase IIProduct Type: Antibody

    Sponsor: Leerink Partners

    Deal Size: $50.0 million Upfront Cash: Undisclosed

    Deal Type: Public Offering June 05, 2025

    blank

    01

    Xilio Therapeutics

    U.S.A
    arrow
    CRS
    Not Confirmed

    Xilio Therapeutics

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Vilastobart,Atezolizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Leerink Partners

    Deal Size : $50.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

    Details : The net proceeds from the offering will be used to advance the clinical development of XTX10 (vilastobart), which is being evaluated for the treatment of mss colorectal cancer.

    Product Name : XTX101

    Product Type : Antibody

    Upfront Cash : Undisclosed

    June 05, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

    Details:

    The net proceeds from the offering will be used to advance the clinical development of XTX10 (vilastobart), which is being evaluated for the treatment of mss colorectal cancer.


    Lead Product(s): Vilastobart,Atezolizumab

    Therapeutic Area: Oncology Brand Name: XTX101

    Study Phase: Phase I/ Phase IIProduct Type: Antibody

    Sponsor: Leerink Partners

    Deal Size: $50.0 million Upfront Cash: Undisclosed

    Deal Type: Public Offering June 02, 2025

    blank

    02

    Xilio Therapeutics

    U.S.A
    arrow
    CRS
    Not Confirmed

    Xilio Therapeutics

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Vilastobart,Atezolizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Leerink Partners

    Deal Size : $50.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

    Details : The net proceeds from the offering will be used to advance the clinical development of XTX10 (vilastobart), which is being evaluated for the treatment of mss colorectal cancer.

    Product Name : XTX101

    Product Type : Antibody

    Upfront Cash : Undisclosed

    June 02, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Xilio Therapeutics Announces Proposed Public Offering

    Details:

    The net proceeds from the offering will be used to advance the clinical development of XTX10 (vilastobart), which is being evaluated for the treatment of mss colorectal cancer.


    Lead Product(s): Vilastobart,Atezolizumab

    Therapeutic Area: Oncology Brand Name: XTX101

    Study Phase: Phase I/ Phase IIProduct Type: Antibody

    Sponsor: Leerink Partners

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Public Offering June 02, 2025

    blank

    03

    Xilio Therapeutics

    U.S.A
    arrow
    CRS
    Not Confirmed

    Xilio Therapeutics

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Vilastobart,Atezolizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Leerink Partners

    Deal Size : Undisclosed

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Xilio Therapeutics Announces Proposed Public Offering

    Details : The net proceeds from the offering will be used to advance the clinical development of XTX10 (vilastobart), which is being evaluated for the treatment of mss colorectal cancer.

    Product Name : XTX101

    Product Type : Antibody

    Upfront Cash : Undisclosed

    June 02, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zai Lab Gets FDA Fast Track for DLL3 ADC ZL-1310 in Small Cell Lung Cancer

    Details:

    ZL-1310 is the Company’s potential first-in-class Delta-like ligand (DLL3) antibody-drug conjugate (ADC), being investigated for the treatment of extensive-stage small cell lung cancer (ES-SCLC).


    Lead Product(s): ZL-1310,Atezolizumab,Carboplatin

    Therapeutic Area: Oncology Brand Name: ZL-1310

    Study Phase: Phase IProduct Type: Antibody-drug Conjugate

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 19, 2025

    blank

    04

    Zai Lab

    China
    arrow
    CRS
    Not Confirmed

    Zai Lab

    China
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ZL-1310,Atezolizumab,Carboplatin

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Zai Lab Gets FDA Fast Track for DLL3 ADC ZL-1310 in Small Cell Lung Cancer

    Details : ZL-1310 is the Company’s potential first-in-class Delta-like ligand (DLL3) antibody-drug conjugate (ADC), being investigated for the treatment of extensive-stage small cell lung cancer (ES-SCLC).

    Product Name : ZL-1310

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    May 19, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Phanes Starts Peluntamig Plus Atezolizumab Clinical Study in Cancer

    Details:

    PT217 (peluntamig) in combination with Roche's anti-PD-L1 monoclonal antibody atezolizumab (TECENTRIQ® ) is being investigated in patients with extensive-stage small cell lung cancer.


    Lead Product(s): Peluntamig,Atezolizumab,Carboplatin

    Therapeutic Area: Oncology Brand Name: PT217

    Study Phase: Phase I/ Phase IIProduct Type: Antibody

    Sponsor: F. Hoffmann-La Roche

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 05, 2025

    blank

    05

    Phanes Therapeutics

    U.S.A
    arrow
    CRS
    Not Confirmed

    Phanes Therapeutics

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Peluntamig,Atezolizumab,Carboplatin

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : F. Hoffmann-La Roche

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Phanes Starts Peluntamig Plus Atezolizumab Clinical Study in Cancer

    Details : PT217 (peluntamig) in combination with Roche's anti-PD-L1 monoclonal antibody atezolizumab (TECENTRIQ® ) is being investigated in patients with extensive-stage small cell lung cancer.

    Product Name : PT217

    Product Type : Antibody

    Upfront Cash : Inapplicable

    May 05, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    ORYZON Doses First Patient in Lung Cancer Trial of Iadademstat with Checkpoint Drugs

    Details:

    ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1. It is being investigated in patients with extensive-stage small cell lung cancer.


    Lead Product(s): Iadademstat,Atezolizumab,Durvalumab

    Therapeutic Area: Oncology Brand Name: ORY-1001

    Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 15, 2025

    blank

    06

    Oryzon Genomics

    Spain
    arrow
    CRS
    Not Confirmed

    Oryzon Genomics

    Spain
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Iadademstat,Atezolizumab,Durvalumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    ORYZON Doses First Patient in Lung Cancer Trial of Iadademstat with Checkpoint Drugs

    Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1. It is being investigated in patients with extensive-stage small cell lung cancer.

    Product Name : ORY-1001

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    April 15, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Immune-Onc Doses First Patient in IO-108 Phase 1b/2 Liver Cancer Study

    Details:

    IO-108 antibody is being evaluated in combination with atezolizumab and bevacizumab for the treatment of locally advanced hepatocellular carcinoma.


    Lead Product(s): IO-108,Atezolizumab,Bevacizumab

    Therapeutic Area: Oncology Brand Name: IO-108

    Study Phase: Phase I/ Phase IIProduct Type: Antibody

    Sponsor: F. Hoffmann-La Roche

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 27, 2025

    blank

    07

    Immune-Onc Therapeutics

    U.S.A
    arrow
    CRS
    Not Confirmed

    Immune-Onc Therapeutics

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : IO-108,Atezolizumab,Bevacizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : F. Hoffmann-La Roche

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Immune-Onc Doses First Patient in IO-108 Phase 1b/2 Liver Cancer Study

    Details : IO-108 antibody is being evaluated in combination with atezolizumab and bevacizumab for the treatment of locally advanced hepatocellular carcinoma.

    Product Name : IO-108

    Product Type : Antibody

    Upfront Cash : Inapplicable

    February 27, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Rznomics Inc. Liver Cancer Drug Candidate Secures Fast Track Designation

    Details:

    RZ-001 is an anti-HCC activity by suppressing hTERT expression selectively in cancer cells. It is being in combination with valganciclovir for the treatment of hepatocellular carcinoma.


    Lead Product(s): RZ-001,Atezolizumab,Valganciclovir Hydrochloride

    Therapeutic Area: Oncology Brand Name: RZ-001

    Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 17, 2025

    blank

    08

    Rznomics

    South Korea
    arrow
    CRS
    Not Confirmed

    Rznomics

    South Korea
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : RZ-001,Atezolizumab,Valganciclovir Hydrochloride

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Rznomics Inc. Liver Cancer Drug Candidate Secures Fast Track Designation

    Details : RZ-001 is an anti-HCC activity by suppressing hTERT expression selectively in cancer cells. It is being in combination with valganciclovir for the treatment of hepatocellular carcinoma.

    Product Name : RZ-001

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    February 17, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Tempest gets FDA Fast Track for Amezalpat in Hepatocellular Carcinoma

    Details:

    TPST-1120 (amezalpat) target of PPARα, it is being investigated as a first-line treament of hepatocellular carcinoma, as a combination with atezolizumab and bevacizumab.


    Lead Product(s): Amezalpat,Atezolizumab,Bevacizumab

    Therapeutic Area: Oncology Brand Name: TPST-1120

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 10, 2025

    blank

    09

    Tempest Therapeutics

    U.S.A
    arrow
    CRS
    Not Confirmed

    Tempest Therapeutics

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Amezalpat,Atezolizumab,Bevacizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Tempest gets FDA Fast Track for Amezalpat in Hepatocellular Carcinoma

    Details : TPST-1120 (amezalpat) target of PPARα, it is being investigated as a first-line treament of hepatocellular carcinoma, as a combination with atezolizumab and bevacizumab.

    Product Name : TPST-1120

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 10, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Genprex Doses First Patient in Phase 2 Expansion of Acclaim-3 Trial in SCLC

    Details:

    Reqorsa Immunogene therapy (quaratusugene ozeplasmid), which is currently being investigated in combination with Tecentriq for extensive-stage small cell lung cancer.


    Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab

    Therapeutic Area: Oncology Brand Name: Reqorsa

    Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 23, 2025

    blank

    10

    Genprex

    U.S.A
    arrow
    CRS
    Not Confirmed

    Genprex

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Quaratusugene Ozeplasmid,Atezolizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Genprex Doses First Patient in Phase 2 Expansion of Acclaim-3 Trial in SCLC

    Details : Reqorsa Immunogene therapy (quaratusugene ozeplasmid), which is currently being investigated in combination with Tecentriq for extensive-stage small cell lung cancer.

    Product Name : Reqorsa

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    January 23, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    01

    GENENTECH INC

    U.S.A
    CRS
    Not Confirmed
    arrow

    GENENTECH INC

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD :

    TE Code :

    ATEZOLIZUMAB

    Brand Name : TECENTRIQ

    Dosage Form : INJECTABLE;INJECTION

    Dosage Strength : 1200MG/20ML

    Approval Date :

    Application Number : 761034

    RX/OTC/DISCN :

    RLD :

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    GENENTECH INC

    U.S.A
    CRS
    Not Confirmed
    arrow

    GENENTECH INC

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD :

    TE Code :

    ATEZOLIZUMAB

    Brand Name : TECENTRIQ

    Dosage Form : INJECTABLE; INJECTION

    Dosage Strength : 1200MG/20ML

    Approval Date :

    Application Number : 761041

    RX/OTC/DISCN :

    RLD :

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    GENENTECH INC

    U.S.A
    CRS
    Not Confirmed
    arrow

    GENENTECH INC

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD :

    TE Code :

    ATEZOLIZUMAB AND HYALURONIDASE-TQJS

    Brand Name : TECENTRIQ HYBREZA

    Dosage Form : INJECTABLE;INJECTION

    Dosage Strength : 125MG;2000UNITS PER ML

    Approval Date :

    Application Number : 761347

    RX/OTC/DISCN :

    RLD :

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Europe

    read-more
    read-more

    01

    Roche Registration GmbH

    Switzerland
    CRS
    Not Confirmed
    arrow

    Roche Registration GmbH

    Switzerland
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Norway

    Atezolizumab

    Brand Name : Tecentriq

    Dosage Form : Concentrate for infusion solution, solution

    Dosage Strength : 1,200 mg

    Packaging : Vials 1 20ml

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Roche Registration GmbH

    Switzerland
    CRS
    Not Confirmed
    arrow

    Roche Registration GmbH

    Switzerland
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Norway

    Atezolizumab

    Brand Name : Tecentriq

    Dosage Form : Solution for injection

    Dosage Strength : 1,875 mg

    Packaging : Vials 1 15ml

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Roche Registration GmbH

    Switzerland
    CRS
    Not Confirmed
    arrow

    Roche Registration GmbH

    Switzerland
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Norway

    Atezolizumab

    Brand Name : Tecentriq

    Dosage Form : Concentrate for infusion solution, solution

    Dosage Strength : 840 mg

    Packaging : Vials 1 14ml

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Roche Pharma (Schweiz) AG

    Switzerland
    CRS
    Not Confirmed
    arrow

    Roche Pharma (Schweiz) AG

    Switzerland
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Switzerland

    Atezolizumabum

    Brand Name : Tecentriq

    Dosage Form : Inf Konz

    Dosage Strength : 1200mg/20ml

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Orifarm AS

    Denmark
    CRS
    Not Confirmed
    arrow

    Orifarm AS

    Denmark
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Denmark
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Norway

    Atezolizumab

    Brand Name : Tecentriq

    Dosage Form : Concentrate for infusion solution, solution

    Dosage Strength : 840 mg

    Packaging : Vials 1 14ml

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Orifarm AS

    Denmark
    CRS
    Not Confirmed
    arrow

    Orifarm AS

    Denmark
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Denmark
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Norway

    Atezolizumab

    Brand Name : Tecentriq

    Dosage Form : Concentrate for infusion solution, solution

    Dosage Strength : 1,200 mg

    Packaging : Vials 1 20ml

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    US Medicaid Prescriptions

    read-more
    read-more

    01

    Brand Name : Tecentriq

    U.S.A
    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Genentech, Inc.

    Atezolizumab

    Drug Cost (USD) : 28,732,491

    Year : 2023

    Prescribers : 409

    Prescriptions : 2598

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Tecentriq

    U.S.A
    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Genentech, Inc.

    Atezolizumab

    Drug Cost (USD) : 24,590,543

    Year : 2022

    Prescribers : 400

    Prescriptions : 2314

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Tecentriq

    U.S.A
    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Genentech, Inc.

    Atezolizumab

    Drug Cost (USD) : 14,535,133

    Year : 2021

    Prescribers : 278

    Prescriptions : 1428

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Tecentriq

    U.S.A
    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Genentech, Inc.

    Atezolizumab

    Drug Cost (USD) : 12,942,335

    Year : 2020

    Prescribers : 234

    Prescriptions : 1300

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Tecentriq

    U.S.A
    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Genentech, Inc.

    Atezolizumab

    Drug Cost (USD) : 9,260,687

    Year : 2019

    Prescribers : 182

    Prescriptions : 969

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Tecentriq

    U.S.A
    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Genentech, Inc.

    Atezolizumab

    Drug Cost (USD) : 3,601,620

    Year : 2018

    Prescribers : 95

    Prescriptions : 413

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Tecentriq

    U.S.A
    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    U.S.A
    arrow
    CRS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Genentech, Inc.

    Atezolizumab

    Drug Cost (USD) : 4,135,067

    Year : 2017

    Prescribers : 104

    Prescriptions : 458

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Regulatory FDF Prices

    read-more
    read-more

    01

    Brand Name : Tecentriq

    Denmark
    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    Denmark
    arrow
    CRS
    Not Confirmed

    Orifarm AS

    Atezolizumab

    Dosage Form : Concentrate for infusion solutio...

    Dosage Strength : 840 mg

    Price Per Pack (Euro) : 2,418.49

    Published in :

    Country : Norway

    RX/OTC/DISCN :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Tecentriq

    Denmark
    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    Denmark
    arrow
    CRS
    Not Confirmed

    Orifarm AS

    Atezolizumab

    Dosage Form : Concentrate for infusion solutio...

    Dosage Strength : 1,200 mg

    Price Per Pack (Euro) : 3,449.67

    Published in :

    Country : Norway

    RX/OTC/DISCN :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Roche Registration GmbH

    Atezolizumab

    Dosage Form : Concentrate for infusion solutio...

    Dosage Strength : 1,200 mg

    Price Per Pack (Euro) : 3,449.67

    Published in :

    Country : Norway

    RX/OTC/DISCN :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Roche Registration GmbH

    Atezolizumab

    Dosage Form : Concentrate for infusion solutio...

    Dosage Strength : 840 mg

    Price Per Pack (Euro) : 2,418.49

    Published in :

    Country : Norway

    RX/OTC/DISCN :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Roche Pharma (Schweiz) AG

    Atezolizumab

    Dosage Form : Inf Konz

    Dosage Strength : 1200mg/20ml

    Price Per Pack (Euro) : 4370.35

    Published in :

    Country : Switzerland

    RX/OTC/DISCN : Class A

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Roche Registration GmbH

    Atezolizumab

    Dosage Form : Solution for injection

    Dosage Strength : 1,875 mg

    Price Per Pack (Euro) : 3,449.67

    Published in :

    Country : Norway

    RX/OTC/DISCN :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Annual Reports

    read-more
    read-more

    01

    Brand Name : Tecentriq

    Atezolizumab

    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Roche

    Atezolizumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 1,931

    2018 Revenue in Millions : 795

    Growth (%) : 143

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Tecentriq

    Atezolizumab

    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Roche

    Atezolizumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 3,051

    2019 Revenue in Millions : 2,089

    Growth (%) : 46

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Tecentriq

    Atezolizumab

    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Roche

    Atezolizumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 3,568

    2020 Revenue in Millions : 2,902

    Growth (%) : 21

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Tecentriq

    Atezolizumab

    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Roche

    Atezolizumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 4,063

    2021 Revenue in Millions : 3,568

    Growth (%) : 14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Tecentriq

    Atezolizumab

    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Roche

    Atezolizumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 4,369

    2022 Revenue in Millions : 4,063

    Growth (%) : 1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Tecentriq

    Atezolizumab

    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Roche

    Atezolizumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 4,010

    2023 Revenue in Millions : 4,369

    Growth (%) : -8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Tecentriq

    Atezolizumab

    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Roche

    Atezolizumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2017 Revenue in Millions : 516

    2016 Revenue in Millions : 166

    Growth (%) : 210

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Tecentriq

    Atezolizumab

    arrow
    CRS
    Not Confirmed

    Brand Name : Tecentriq

    Switzerland
    arrow
    CRS
    Not Confirmed

    Roche

    Atezolizumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2018 Revenue in Millions : 780

    2017 Revenue in Millions : 492

    Growth (%) : 59%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Market Place

    Do you need sourcing support? Ask us

    FDF DOSSIERS

    read-more
    read-more
    Poland.png
    Tender// Various Finished Dosage Formulations needed in Poland [ENA09429]
    Wielkopolskie Center of Pulmonology and Thoracic Surgery Eugenia and Janusz Zeyland SP ZOZ is looking for suppliers of Various Finished Dosage Formulations. The deadline is 19-Jan-2021. 1. Teicoplanin (200 mg & 400 mg) Solution for Injection. The required quantity is 10 units for each. 2. Pembrolizumab (100 mg/ 4 ml) Solution for Injection. The required quantity is 230 units. 3. Atezolizumab (1200 mg/ 20 ml) Solution for Injection. The required quantity is 110 units. 4. Nintedanib (100 mg & 150 mg) Capsules. The required quantity is 15 units and 60 units respectively. 5. Mepolizumab (100 mg) Pen. The required is 30 units. 6. Mepolizumab (100 mg) Syringe. The required quantity is 10 units. 7. Amiodarone HCl (150 mg/ 3 ml) Ampoule in the packaging of 6 ampoules. The required quantity is 40 units. 8. Drotaverine HCl (40 mg/ 2 ml) Ampoule in the packaging of 5 ampoules. The required quantity is 40 units. 9. Tranexamic acid (500 mg/ 5 ml) Ampoule in the packaging of 5 ampoules. The required quantity is 150 units. 10. Rasburicase (1.5 mg) Vials in the packaging of 3 vials. The required quantity is 1 unit. 11. Enoxaparin Sodium (100 mg/ 1 ml, 20 mg/ 0.2 ml, 40 mg/ 0.4 ml, 60 mg/ 0.6 ml & 80 mg/ 0.8 ml). The required quantity is 60 units, 20 units, 900 units, 250 units and 200 units respectively.
    07 Jan 2021

    Reply

    07 Jan 2021

    Reply text-arrow

    Reply Comment (3)

    07 Jan 2021

    PharmaCompass
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search